Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.55 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28118170 | 0.87 | ATM (0.58) | MTNR1AMTNR1BATMMEN1KMT2A | |
| SCHEMBL8398835 | 0.86 | TAAR1 (0.56) | MTNR1AMTNR1BATMMEN1KMT2A | |
| SCHEMBL266821 | 0.85 | L3MBTL1 (0.64) | MTNR1AMTNR1BMEN1KMT2ATSHR | |
| SCHEMBL29737506 | 0.85 | L3MBTL1 (0.64) | MTNR1AMTNR1BMEN1KMT2ATSHR | |
| SCHEMBL4479762 | 0.82 | KMT2A (0.54) | ATMMEN1KMT2ATSHRMAPT | |
| SCHEMBL29014549 | 0.81 | TSHR (0.57) | ATMMEN1KMT2ATSHRMAPT | |
| SCHEMBL12731509 | 0.81 | ATM (0.52) | MTNR1AMTNR1BATMMEN1KMT2A | |
| SCHEMBL3005345 | 0.81 | TAAR1 (0.54) | MTNR1AMTNR1BATMMEN1KMT2A | |
| SCHEMBL30027909 | 0.80 | MEN1 (0.58) | MTNR1AMTNR1BATMMEN1KMT2A | |
| SCHEMBL468013 | 0.80 | MEN1 (0.58) | MTNR1AMTNR1BATMMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170349607-A1 | COMPOUNDS ACTIVE TOWARDS BROMODOMAINS | NUEVOLUTION A/S (DK) | 2017-12-07 | — | — | US | disclosed |
| US-20160257651-A1 | NOVEL COMPOUND WITH ANTIBACTERIAL ACTIVITY | JUNTENDO EDUCATIONAL FOUNDATION (JP) | 2016-09-08 | — | — | US | disclosed |
| EP-1904583-B1 | PIGMENT DISPERSIONS WITH POLYMERIC DISPERSANTS HAVING PENDING CHROMOPHORE GROUPS. | AGFA GRAPHICS NV (BE) | 2012-03-21 | — | — | EP | disclosed |
| US-20110207860-A1 | Inkjet Ink Compositions Comprising Polymeric Dispersants Having Attached Chromophore Groups | CABOT CORPORATION (US) | 2011-08-25 | — | — | US | disclosed |
| US-7947761-B2 | Inkjet ink compositions comprising polymeric dispersants having attached chromophore groups | CABOT CORPORATION (US) | 2011-05-24 | — | — | US | disclosed |
| EP-1904592-B1 | PHENYLAZO-ACETOACETANILIDE DERIVATIVES WITH A POLYMER! ZABLE FUNCTIONAL GROUP AND RELATED COMPOUNDS AS MONOMERS FOR PREPARING POLYMERIC PIGMENT DISPERSANTS FOR INKJET INKS | AGFA GRAPHICS NV (BE) | 2009-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160257651-A1 | NOVEL COMPOUND WITH ANTIBACTERIAL ACTIVITY | SLC11A2, RELA, NFKBIA | MTNR1A 3125/4885MTNR1B 2802/4885ATM 3958/4885 |
| US-20170349607-A1 | COMPOUNDS ACTIVE TOWARDS BROMODOMAINS | BRD4, BRD3, BRDT | MTNR1A 3116/4885MTNR1B 2944/4885ATM 568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.